Sebastian Schneeweiss is Professor of Medicine and Epidemiology at Harvard Medical School and Vice Chief of the Division of Pharmacoepidemiology and Pharmacoeconomics of the Dept. of Medicine, Brigham and Women’s Hospital.
He is Principal Investigator of the Harvard-Brigham Drug Safety Research Center funded by FDA/CDER, and Methods Lead of the FDA Mini Sentinel program. His research is funded by multiple grants from NIH, PCORI, AHRQ, and FDA and focuses on the comparative effectiveness and safety of biopharmaceuticals and analytic methods to improve the validity of epidemiologic studies using complex healthcare databases particularly for newly marketed medical products. His work is published in high-ranking journals.
Dr. Schneeweiss is Past President of the International Society for Pharmacoepidemiology and is Fellow of the American College of Epidemiology, the American College of Clinical Pharmacology, and the International Society for Pharmacoepidemiology. He is voting consultant to the FDA Drug Safety and Risk Management Advisory Committee and member of the Methods Committee of the Patient Centered Outcomes Research Institute.
He received his medical training at the University of Munich Medical School and his doctoral degree in Pharmacoepidemiology from Harvard.